
Amaxa® Cell Line Nucleofector® Kit V


For MCF7

Human mammary gland adenocarcinoma cell line; adherent epithelial

Example for Nucleofection® of MCF7 with eGFP cDNA



MCF7 cells were transfected using the Cell Line Nucleofector® Kit V, program P-020 and 2 µg of a plasmid encoding the enhanced green fluorescent protein eGFP. 24 hours post Nucleofection® the cells were analyzed by light (A) and fluorescence microscopy (B).



Average transfection efficiency of MCF7 cell line. Cells were transfected with Nucleofector® Program P-020 and 2 µg of a plasmid encoding the enhanced green fluorescent protein eGFP. 5, 24 and 48 hours post Nucleofection® cells were analyzed by flow cytometry. Cell viability is around 60% 24 hours post Nucleofection®.

Product Description

Cat. No.		VCA-1003
Size (reactions)		25
Cell Line Nucleofector [®] Solution V		2.25 ml (2.05 ml + 10% overfill)
Supplement		0.5 ml (0.45 ml + 10% overfill)
pmaxGFP® Vector (0.5 µg/µl in 10 mM Tris pH 8.0)		30 µg
Certified cuvettes		25
Plastic pipettes		25
Storage and stability	Store Nucleofector® Soluti	on, Supplement and pmaxGFP [®] Vector at 4°C. For long-term storage,
	pmaxGFP® Vector is ideally	stored at -20°C. The expiration date is printed on the solution box. Once the
	Nucleofector [®] Supplement	is added to the Nucleofector® Solution it is stable for three months at 4°C.

Required Material

Note

Please make sure that the entire supplement is added to the Nucleofector[®] Solution. The ratio of Nucleofector[®] Solution to supplement is 4.5:1. For a single reaction use 82 µl of Nucleofector[®] Solution plus 18 µl of supplement to make 100 µl of total reaction volume.

- Nucleofector[®] Device
- Supplemented Nucleofector® Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP® Vector
- Substrate of interest, highly purified, preferably by using endotoxin free Kits; A260: A280 ratio should be at least 1.8
- 6-well culture dish or culture system of your choice
- For detaching: 0.05% trypsin/0.02% EDTA and supplemented culture media or PBS/0.5% BSA
- Culture medium: Eagle's Minimum Essential Media (EMEM), 0.01 mg/ml bovine insulin and 10% fetal calf serum (FCS))
- Prewarm appropriate volume of culture medium to 37°C (1.5 ml media per sample)
- Appropriate number of cells (2 x 10⁶ cells per sample)
 Minimal cell number: 8 x 10⁵ cells (a lower cell number may lead to a major increase in cell mortality)
 Maximum cell number: 4 x 10⁶

1. Pre Nucleofection®

Cell culture recommendations

- 1.1 Replace media 2 times a week (30 ml per 162 cm² flask)
- 1.2 Cells should be passaged at 75 80% confluency
- 1.3 Seed out 2×10^5 cells/cm²
- 1.4 Subculture 3 4 days before Nucleofection®
- 1.5~ For Nucleofection $^{\rm @}$ Cells should be 75-80% confluent

Trypsinization

- 1.6 Remove media from the cultured cells and wash cells once with PBS; use at least same volume of PBS as culture media
- 1.7 For harvesting, incubate the cells at 37°C with e.g. 0.05% trypsin/0.02% EDTA
- 1.8 Inactivate trypsinization reaction with supplemented culture media or PBS/0.5% BSA

2. Nucleofection®

One Nucleofection® Sample contains

2 x 10⁶ cells

 $1 - 2 \mu g \text{ plasmid DNA}$ (in $1 - 5 \mu H_2 0 \text{ or TE}$) or $2 \mu g \text{ pmaxGFP}^{\circ}$ Vector or 30 - 300 nM siRNA (3 - 30 pmol/sample)

100 µl Cell Line Nucleofector® Solution V

- 2.1 Please make sure that the entire supplement is added to the Nucleofector® Solution
- 2.2 Prepare 6-well plates by filling appropriate number of wells with 1.5 ml of supplemented culture media and pre-incubate/equilibrate plates in a humidified 37°C/5% CO₂ incubator
- 2.3 Harvest the cells by trypsinization (please see 1.6 1.8)
- 2.4 Count an aliquot of the trypsinized cells and determine cell density
- 2.5 Centrifuge the required number of cells (2 x 10⁶ cells per sample) at 90xg for 10 minutes at room temperature
- 2.6 Resuspend the cell pellet carefully in 100 µl room temperature Nucleofector[®] Solution per sample. As leaving cells in Nucleofector[®] Solution for extended periods of time (longer than 15 minutes) may lead to reduced transfection efficiency and viability it is important to work as quickly as possible
- 2.7 Combine 100 μl of cell suspension with 1 2 μg DNA or 30 nM 300 nM siRNA (3 30 pmol/sample) or other substrates
- 2.8 Transfer cell/DNA suspension into certified cuvette (sample must cover the bottom of the cuvette without air bubbles). Close the cuvette with the cap
- 2.9 Select the appropriate Nucleofector® Program P-020 for high transfection efficiency or E-014 for high viability and short term expression (P-20 or E-14 for Nucleofector® | Device)
- 2.10 Insert the cuvette with cell/DNA suspension into the Nucleofector[®] Cuvette Holder and apply the selected program
- 2.11 Take the cuvette out of the holder once the program is finished
- 2.12 Add ~500 μl of the pre-equilibrated culture media to the cuvette and gently transfer the sample immediately into the 6-well plate (final volume 1.5 ml media per well/sample). Use the supplied pipettes and avoid repeated aspiration of the sample

3. Post Nucleofection®

3.1 Incubate the cells in a humidified 37°C/5% CO_2 incubator until analysis. Gene expression is often detectable already after only 4 – 8 hours

Additional Information

For an up-to-date list of all Nucleofector® References, please refer to: www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

USA/Canada Phone: 800 521 0390 (toll-free) Fax: 301 845 8338 E-mail: scientific.support@lonza.com Europe and Rest of World Phone: +49 221 99199 400 Fax: +49 221 99199 499 E-mail: scientific.support.eu@lonza.com

Lonza Cologne AG 50829 Cologne, Germany

Please note that the Amaxa® Nucleofector® Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans.

The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well System and 96-well Nucleocuvette® plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne AG.

Amaxa, Nucleofector, Nucleofection and maxGFP are either registered trademarks or trademarks of the Lonza Cologne AG in Germany and/or U.S. and/or other countries.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2009, Lonza Cologne AG. All rights reserved DCV-1014 05/09